Filing Details
- Accession Number:
- 0001387131-21-002710
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-19 16:50:09
- Reporting Period:
- 2021-02-17
- Accepted Time:
- 2021-02-19 16:50:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1656536 | Decibel Therapeutics Inc. | DBTX | Pharmaceutical Preparations (2834) | X0 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1131399 | Plc Glaxosmithkline | 980 Great West Road Brentford Middlesex X0 TW8 9GS | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-17 | 458,487 | $0.00 | 458,487 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2021-02-17 | 247,324 | $0.00 | 705,811 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2021-02-17 | 327,852 | $0.00 | 1,033,663 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2021-02-17 | 150,000 | $18.00 | 1,183,663 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2021-02-17 | 7,119,850 | $0.00 | 458,487 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2021-02-17 | 3,125,000 | $0.00 | 247,324 | $0.00 |
| Common Stock | Series D Preferred Stock | Disposition | 2021-02-17 | 1,737,619 | $0.00 | 327,852 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The Series A Preferred Stock automatically converted into common stock on a 15.529-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- The shares reported herein are held of record by GSK Equity Investments, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
- The Series C Preferred Stock automatically converted into common stock on a 12.6352-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- The Series D Preferred Stock automatically converted into common stock on a 5.3-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- GSK Equity Investments, Limited purchased 150,000 shares of common stock in connection with the issuer's initial public offering.
Billionaire Hedge Funds
